Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion.

Tytuł:
Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion.
Autorzy:
Hong SM; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jung D; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Medical Science, Graduate School, University of Ulsan, Seoul, Republic of Korea.
Kiemen A; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Gaida MM; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Institute of Pathology, University Medical Center Mainz, Mainz, Germany.
Yoshizawa T; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Braxton AM; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Noë M; Department of Oncology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Lionheart G; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Oshima K; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Thompson ED; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Oncology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Burkhart R; Department of Surgery, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Wu PH; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Wirtz D; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Hruban RH; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. .; Department of Oncology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. .
Wood LD; Department of Pathology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. .; Department of Oncology, the Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. .
Źródło:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2020 Apr; Vol. 33 (4), pp. 639-647. Date of Electronic Publication: 2019 Nov 07.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Video-Audio Media
Język:
English
Imprint Name(s):
Publication: 2023- : [New York] : Elsevier Inc.
Original Publication: Baltimore, MD : Williams & Wilkins, c1988-
MeSH Terms:
Epithelial-Mesenchymal Transition*
Imaging, Three-Dimensional*
Microscopy, Confocal*
Carcinoma, Pancreatic Ductal/*pathology
Pancreatic Neoplasms/*pathology
Veins/*pathology
Aged ; Aged, 80 and over ; Antigens, CD/analysis ; Baltimore ; Biomarkers, Tumor/analysis ; Cadherins/analysis ; Carcinoma, Pancreatic Ductal/chemistry ; Carcinoma, Pancreatic Ductal/surgery ; Desmin/analysis ; Female ; Fluorescent Antibody Technique, Indirect ; Germany ; Humans ; Keratin-19/analysis ; Male ; Middle Aged ; Neoplasm Invasiveness ; Pancreatic Neoplasms/chemistry ; Pancreatic Neoplasms/surgery ; Platelet Endothelial Cell Adhesion Molecule-1/analysis ; Tumor Suppressor Protein p53/analysis ; Veins/chemistry
References:
J Pathol. 2019 Jun;248(2):131-141. (PMID: 30838636)
Gut. 2015 Nov;64(11):1783-9. (PMID: 25636698)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
World J Gastroenterol. 2013 Jun 28;19(24):3761-9. (PMID: 23840114)
Ann Surg Oncol. 2018 Apr;25(4):1043-1051. (PMID: 29302820)
Mod Pathol. 2005 Jun;18(6):752-61. (PMID: 15696124)
J Cell Physiol. 2017 Dec;232(12):3261-3272. (PMID: 28079253)
Am J Surg Pathol. 2012 Feb;36(2):235-41. (PMID: 22082604)
Pancreatology. 2017 Nov - Dec;17(6):951-955. (PMID: 28844697)
Cancer Res. 2008 May 15;68(10):3645-54. (PMID: 18483246)
Hepatogastroenterology. 2014 Sep;61(134):1756-61. (PMID: 25436375)
Clin Cancer Res. 2008 Jan 15;14(2):412-8. (PMID: 18223216)
Am J Surg Pathol. 2004 May;28(5):613-20. (PMID: 15105649)
Mol Oncol. 2017 Jul;11(7):770-780. (PMID: 28544498)
Cancer Res Treat. 2016 Oct;48(4):1222-1228. (PMID: 26875194)
Adv Anat Pathol. 2019 Jan;26(1):31-39. (PMID: 30256228)
Oncogene. 2008 Nov 24;27(55):6920-9. (PMID: 19029934)
Am J Pathol. 2018 Jul;188(7):1530-1535. (PMID: 29684363)
Cancer. 2012 Feb 1;118(3):628-38. (PMID: 21751188)
J Clin Invest. 2009 Jun;119(6):1429-37. (PMID: 19487819)
Sci Adv. 2019 Aug 28;5(8):eaav6789. (PMID: 31489365)
Cell. 2019 Jun 27;178(1):160-175.e27. (PMID: 31155233)
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61. (PMID: 11526241)
Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099)
Mol Cancer. 2016 Feb 24;15:18. (PMID: 26905733)
Jpn J Surg. 1990 Sep;20(5):545-52. (PMID: 2243447)
Grant Information:
P50 CA062924 United States CA NCI NIH HHS; T32 CA130840 United States CA NCI NIH HHS
Substance Nomenclature:
0 (Antigens, CD)
0 (Biomarkers, Tumor)
0 (CDH1 protein, human)
0 (Cadherins)
0 (Desmin)
0 (KRT19 protein, human)
0 (Keratin-19)
0 (PECAM1 protein, human)
0 (Platelet Endothelial Cell Adhesion Molecule-1)
0 (TP53 protein, human)
0 (Tumor Suppressor Protein p53)
Entry Date(s):
Date Created: 20191109 Date Completed: 20210125 Latest Revision: 20231005
Update Code:
20240105
PubMed Central ID:
PMC10548439
DOI:
10.1038/s41379-019-0409-3
PMID:
31700162
Czasopismo naukowe
Venous invasion is three times more common in pancreatic cancer than it is in other major cancers of the gastrointestinal tract, and venous invasion may explain why pancreatic cancer is so deadly. To characterize the patterns of venous invasion in pancreatic cancer, 52 thick slabs (up to 5 mm) of tissue were harvested from 52 surgically resected human ductal adenocarcinomas, cleared with a modified iDISCO method, and labeled with fluorescent-conjugated antibodies to cytokeratin 19, desmin, CD31, p53 and/or e-cadherin. Labeled three-dimensional (3D) pancreas cancer tissues were visualized with confocal laser scanning or light sheet microscopy. Multiple foci of venous and even arterial invasion were visualized. Venous invasion was detected more often in 3D (88%, 30/34 cases) than in conventional 2D slide evaluation (75%, 25/34 cases, P < 0.001). 3D visualization revealed pancreatic cancer cells crossing the walls of veins at multiple points, often at points where preexisting capillary structures bridge the blood vessels. The neoplastic cells often retained a ductal morphology (cohesive cells forming tubes) as they progressed from a stromal to intravenous location. Although immunolabeling with antibodies to e-cadherin revealed focal loss of expression at the leading edges of the cancers, the neoplastic cells within veins expressed e-cadherin and formed well-oriented glands. We conclude that venous invasion is almost universal in pancreatic cancer, suggesting that even surgically resectable PDAC has access to the venous spaces and thus the ability to disseminate widely. Furthermore, we observe that sustained epithelial-mesenchymal transition is not required for venous invasion in pancreatic cancer.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies